sourc
cdc
impact
vaccin
univers
recommend
children
us
mmwr
modifi
vaccin
one
signific
public
health
intervent
ever
made
spare
million
peopl
infecti
diseas
calcul
use
current
avail
vaccin
save
eight
million
live
annual
correspond
one
person
save
everi
five
second
remark
result
achiev
year
vaccin
histori
larg
base
two
basic
simpl
technolog
inactiv
toxin
pathogen
formaldehyd
treatment
first
perform
glenni
hopkin
ramon
stabl
attenu
pathogen
serial
passag
vitro
easi
technolog
appli
develop
vaccin
use
worldwid
control
even
erad
mani
infecti
diseas
one
brilliant
success
vaccin
erad
smallpox
viru
estim
date
smallpox
erad
spare
global
commun
million
new
smallpox
victim
million
death
diseas
annual
save
result
vaccin
stop
hospit
abl
convert
use
estim
excess
us
million
year
vaccin
also
result
elimin
polioviru
america
western
pacif
europ
june
goal
global
polio
erad
initi
interrupt
transmiss
wild
polioviru
lead
global
certif
overal
sinc
initi
launch
number
case
fallen
estim
case
case
report
first
three
month
period
number
polioinfect
countri
reduc
moreov
incid
seven
frighten
diseas
diphtheria
measl
rubella
mump
pertussi
haemophilu
influenza
type
b
hib
tetanu
fallen
state
relat
vaccin
introduc
see
tab
chiron
vaccin
via
fiorentina
siena
itali
histor
technolog
vaccin
product
achiev
remark
success
battl
infecti
diseas
last
sever
million
year
exist
earth
microorgan
learnt
escap
surveil
immun
system
either
hide
host
respons
develop
capac
infect
differ
host
two
main
mechan
pathogen
defens
explain
vaccin
sever
pathogen
hiv
hcv
streptococcu
pyogen
staphylococcu
aureu
plasmodium
falciparum
schistosoma
spp
other
difficult
develop
yet
avail
moreov
last
year
big
revolut
microbi
ecolog
pathogen
circul
sinc
mani
year
whose
exist
ignor
discov
hcv
metapneumoviru
etc
old
pathogen
chang
geograph
habitat
introduc
new
area
becom
endem
eg
west
nile
viru
north
america
complet
new
pathogen
emerg
pose
seriou
threat
human
health
hiv
sar
coronaviru
etc
pathogen
thought
control
reemerg
mycobacterium
tuberculosi
etc
tab
soon
clear
old
vaccin
strategi
unabl
face
new
challeng
pose
infecti
diseas
modern
approach
need
therefor
begin
take
advantag
better
understand
immun
system
emerg
recombin
dna
technolog
new
vaccin
develop
tab
moreov
nowaday
rang
technolog
strategi
avail
vaccin
develop
extrem
broad
avail
whole
genom
sequenc
mani
pathogen
consid
real
revolut
tabl
univers
routin
vaccin
reduc
incid
nine
harm
diseas
us
erad
two
smallpox
polio
max
common
knowledg
capsular
polysaccharid
mani
import
bacteri
pathogen
major
virul
factor
vaccin
use
purifi
polysaccharid
could
protect
peopl
diseas
polysaccharid
vaccin
develop
neisseria
meningitidi
serogroup
mena
group
c
men
c
group
meni
group
men
late
h
influenza
type
b
type
streptococcu
pneumonia
earli
salmonella
typhi
mid
howev
use
vaccin
inadequ
polysaccharid
tindepend
antigen
immunogen
efficaci
poor
absent
infant
unsuit
includ
infant
routin
immun
schedul
solut
found
coval
link
sugar
carrier
protein
conjug
procedur
convert
tindepend
antigen
tdepend
one
provid
sourc
appropri
tcell
epitop
present
carrier
protein
conjug
technolog
one
biggest
achiev
novel
vaccin
strategi
capac
transform
poor
immunogen
polysaccharid
excel
immunonovel
vaccin
strategi
first
conjug
vaccin
develop
one
haemophilu
influenza
type
b
hib
hib
respiratori
pathogen
caus
wide
spectrum
human
infect
avail
hib
conjug
vaccin
hib
lead
caus
bacteri
mening
especi
infant
develop
develop
countri
worldwid
result
substanti
morbid
mortal
first
hib
conjug
vaccin
introduc
us
decemb
children
month
age
older
subsequ
immunogen
vaccin
introduc
us
well
mani
countri
earli
use
infant
age
two
month
within
year
effect
public
impact
hib
conjug
vaccin
hib
diseas
demonstr
countri
introduc
vaccin
us
annual
case
hib
invas
diseas
among
children
five
year
age
decreas
prevaccin
era
less
gener
decreas
incid
diseas
exceed
predict
basi
estim
proport
popul
complet
immun
suggest
vaccin
use
abl
gener
herd
immun
topic
mani
studi
shown
hib
conjug
vaccin
abl
reduc
nasopharyng
carriag
give
major
contribut
herd
immun
precis
hib
conjug
immun
reduc
nasopharyng
colon
whether
impact
due
decreas
acquisit
decreas
durat
carriag
clear
addit
work
immunolog
microbiolog
transmiss
carriag
need
clarifi
issu
hand
reduct
hib
carriag
may
open
ecolog
nich
h
influenza
nontyp
b
strain
maria
lattanzi
rino
rappuoli
seven
serotyp
first
licens
conjug
vaccin
account
isol
blood
cerebrospin
fluid
children
age
year
us
compar
isol
older
children
adult
us
isol
young
children
latin
america
asia
sevenval
conjug
pneumococc
vaccin
recommend
us
infant
three
primari
dose
approxim
month
age
one
booster
dose
age
month
vaccin
repeat
success
hib
conjug
vaccin
show
high
efficaci
prevent
mening
efficaci
although
less
extent
prevent
pneumonia
acut
otiti
media
due
vaccin
serotyp
moreov
sever
studi
establish
conjug
vaccin
effect
also
reduc
nasopharyng
carriag
serotyp
cover
vaccin
potenti
extend
benefit
beyond
children
vaccin
post
licensur
evalu
efficaci
sevenval
conjug
vaccin
found
reduct
diseas
greater
percentag
children
vaccin
evid
herd
immun
neisseria
mening
group
c
conjug
vaccin
began
clinic
develop
end
extens
clinic
studi
prove
safe
capabl
induc
highli
bactericid
boostabl
immun
respons
infant
children
vaccin
first
introduc
unit
kingdom
late
use
countrywid
vaccin
initi
populationbas
activ
surveil
monitor
agespecif
capsular
groupspecif
incid
diseas
estim
vaccin
coverag
result
impress
within
month
vaccin
introduct
case
menc
diseas
almost
disappear
vaccin
popul
estim
vaccin
efficaci
target
age
group
accord
larg
carriag
studi
perform
unit
kingdom
vaccin
induc
also
decreas
carriag
menc
strain
evid
increas
carriag
menb
isol
capsular
group
moreov
vaccin
provid
evid
herd
immun
also
reduct
menc
diseas
unvaccin
individu
rang
percent
year
old
percent
year
old
sinc
menc
conjug
vaccin
licens
mani
european
countri
also
canada
australia
either
routin
infant
immun
catchup
program
vari
form
multival
meningococc
conjug
vaccin
contain
group
c
clinic
develop
introduct
vaccin
routin
infant
andor
toddler
immun
program
could
substanti
effect
incid
meningococc
diseas
discov
protect
toward
hepat
b
correl
presenc
antibodi
surfac
antigen
viru
hbsag
circul
bloodstream
infect
subject
larg
quantiti
discoveri
led
develop
first
gener
plasmaderiv
hbsag
subunit
vaccin
first
licens
us
concern
safeti
blood
product
advanc
recombin
dna
technolog
conduct
develop
secondgener
recombin
subunit
vaccin
produc
yeast
mammalian
cell
first
licens
us
applic
recombin
dna
technolog
advantag
produc
safer
vaccin
plasmaderiv
one
unlimit
suppli
recombin
hbv
vaccin
highli
effect
standard
cours
three
dose
induc
protect
level
antihb
ie
miuml
healthi
infant
children
adolesc
healthi
adult
younger
year
age
immunogen
drop
howev
age
year
vaccine
develop
protect
anti
hb
titer
moreov
vaccin
prevent
develop
chronic
hepat
least
earlyvaccin
infant
born
hbeagposit
mother
costbenefit
analys
strongli
support
introduct
univers
immun
hbv
newborn
sinc
call
countri
add
hepat
b
vaccin
nation
childhood
immun
schedul
substanti
progress
made
implement
recommend
end
countri
worldwid
introduc
vaccin
substanti
help
achiev
goal
given
global
allianc
vaccin
immun
gavi
vaccin
fund
sinc
began
provid
technic
financi
support
introduc
routin
hbv
immun
world
poorest
countri
effect
routin
infant
hbv
immun
significantli
reduc
elimin
preval
chronic
hbv
infect
demonstr
varieti
countri
set
experi
taiwan
particularli
impress
univers
vaccin
decreas
preval
hbsag
carriag
children
younger
year
age
moreov
rate
hepatocellular
carcinoma
hcc
among
cohort
children
born
routin
infant
immun
start
mid
declin
greater
result
clearli
show
hbv
vaccin
first
success
anticanc
vaccin
open
way
anticanc
vaccin
like
vaccin
human
papilloma
viru
hpv
caus
cervic
cancer
helicobact
pylori
respons
mani
gastric
cancer
first
exampl
vaccin
develop
new
ration
strateg
design
take
advantag
power
molecular
biolog
genom
technolog
recombin
acellular
pertussi
vaccin
vaccin
compos
whole
kill
bordetella
pertussi
cell
avail
mass
vaccin
sinc
late
vaccin
efficaci
prevent
diseas
presenc
sever
advers
reaction
although
proof
exist
caus
vaccin
brought
drop
vaccin
complianc
stress
need
new
safer
vaccin
consider
amount
work
initi
requir
identifi
bacteri
antigen
respons
induct
protect
pertussi
toxin
pt
identifi
major
protect
antigen
antigen
adenyl
cyclas
filament
haemagglutinin
fha
pertactin
fimbria
found
provid
help
protect
immun
sever
research
develop
acellular
pertussi
vaccin
contain
purifi
pt
inactiv
old
classic
chemic
treatment
formaldehyd
glutaraldehyd
howev
recogn
treatment
pt
may
associ
signific
revers
rate
overcom
problem
pertussi
toxin
detoxifi
use
power
tool
molecular
biolog
make
stabl
chang
sitedirect
mutagenesi
amino
acid
respons
toxic
pertussi
toxin
molecular
approach
allow
develop
natur
nontox
molecul
inactiv
ration
design
need
denatur
chemic
treatment
genet
detoxifi
pt
success
shown
safeti
immunogen
clinic
trial
adult
volunt
infant
children
either
monoval
mutant
pt
alon
associ
fha
pertactin
also
fha
pertactin
associ
diphtheria
tetanu
toxoid
dtap
trial
show
differ
acellular
vaccin
formul
contain
nontox
pt
mutant
extrem
safe
much
safer
wholecel
pertussi
vaccin
furthermor
formul
induc
high
titer
antipt
neutral
antibodi
strong
antigenspecif
tcell
prolif
respons
interestingli
enough
five
six
year
primari
immun
schedul
vaccin
still
exhibit
efficaci
antigenspecif
antibodi
tcell
respons
still
detect
signific
level
new
strategi
use
develop
genet
detoxifi
acellular
pertussi
vaccin
show
approach
provid
tremend
advantag
elicit
high
protect
immun
respons
low
amount
antigen
despit
introduct
new
strategi
conjug
recombin
dna
etc
one
major
issu
develop
new
vaccin
identif
protect
antigen
microorgan
biochem
immunolog
microbiolog
method
success
mani
case
requir
pathogen
grown
laboratori
condit
timeconsum
allow
identif
abund
antigen
purifi
quantiti
suitabl
vaccin
test
unfortun
mani
instanc
abund
protein
could
good
vaccin
candid
moreov
antigen
express
vivo
infect
could
express
vitro
extent
furthermor
deal
noncultiv
pathogen
approach
vaccin
develop
avail
complet
genom
sequenc
freeliv
organ
h
influenza
mark
begin
genom
era
open
novel
strategi
vaccin
design
possibl
determin
whole
sequenc
genom
bacteri
viral
parasit
led
idea
use
genom
inform
discov
novel
antigen
miss
convent
vaccinolog
approach
call
revers
vaccinolog
involv
comput
silico
analysi
microbi
genom
sequenc
predict
antigen
like
vaccin
candid
success
genomicbas
strategi
vaccin
develop
highli
depend
criteria
use
silico
select
potenti
antigen
usual
secret
extracellular
protein
easili
access
antibodi
intracellular
one
sever
approach
use
mine
genom
sequenc
appropri
combin
variou
algorithm
critic
evalu
inform
gener
essenti
proper
select
antigen
silico
approach
result
select
larg
number
gene
therefor
necessari
use
simpl
procedur
allow
larg
number
gene
clone
express
like
robot
pcr
product
pcr
reaction
clone
screen
express
heterolog
system
success
express
depend
predict
local
protein
integr
transmembran
protein
proven
particularli
difficult
produc
recombin
techniqu
e
coli
purifi
recombin
protein
use
immun
mice
postimmun
sera
analyz
verifi
computerpredict
surfac
local
polypeptid
abil
elicit
quantit
qualit
immun
protect
respons
genom
approach
mani
novel
featur
advantag
need
cultiv
pathogen
whole
process
start
silico
could
equal
appli
cultiv
noncultiv
microorgan
pathogen
danger
handl
studi
easili
commens
virtual
protein
antigen
encod
pathogen
genom
could
becom
vaccin
candid
regardless
whether
express
vitro
vivo
abund
scarc
process
allow
identif
antigen
seen
convent
method
discoveri
novel
antigen
work
total
differ
paradigm
unfortun
revers
vaccinolog
suffer
limit
relat
incomplet
knowledg
vaccin
immunolog
ratelimit
step
process
link
rariti
often
absenc
wide
accept
correl
protect
reliabl
anim
model
infect
constraint
approach
inabl
identifi
nonprotein
antigen
polysaccharid
restrict
antigen
glycolipid
repres
new
promis
vaccin
candid
meningococcu
b
repres
first
exampl
applic
genom
approach
demonstr
power
novel
strategi
target
antigen
identif
convent
approach
menb
vaccin
develop
ineffect
year
capsular
polysaccharidebas
approach
extrem
success
major
meningococc
serogroup
use
strain
menb
capsular
polysaccharid
ident
wide
distribut
human
carbohydr
nacetyl
neuramin
acid
polysial
acid
condit
make
polysaccharid
poor
immunogen
human
also
potenti
gener
autoantibodi
hand
proteinbas
approach
develop
use
surfaceexpos
protein
contain
outer
membran
vesicl
omv
shown
efficaci
clinic
trial
homolog
strain
especi
children
five
year
age
high
sequenc
variabl
major
protein
antigen
use
revers
vaccinolog
dna
fragment
screen
comput
analysi
n
meningitidi
sequenc
project
progress
screen
aim
select
protein
predict
surfac
bacterium
homolog
known
bacteri
factor
involv
pathogenesi
virul
clearanc
cytoplasm
protein
known
neisseria
antigen
gene
predict
code
surfaceexpos
membraneassoci
protein
recogn
success
clone
e
coli
express
achiev
protein
purifi
test
local
immunogen
protect
efficaci
anim
model
protein
found
surfac
expos
abl
induc
complementmedi
bactericid
antibodi
respons
convinc
indic
capabl
induc
protect
immun
addit
test
appropri
protein
candid
antigen
confer
protect
heterolog
strain
protein
evalu
gene
presenc
phase
variat
sequenc
conserv
panel
genet
divers
menb
strain
repres
global
divers
natur
n
meningitidi
popul
select
antigen
abl
induc
crossprotect
heterolog
strain
demonstr
new
antigen
good
candid
clinic
develop
vaccin
menb
impress
notic
within
month
genom
approach
allow
discoveri
potenti
vaccin
candid
previou
year
convent
research
success
menb
project
togeth
avail
increas
number
genom
sequenc
faster
faster
develop
bioinformat
tool
encourag
applic
revers
vaccinolog
approach
mani
pathogen
nowaday
approach
wide
use
develop
vaccin
candid
pathogen
convent
approach
fail
far
potenti
genom
approach
extens
could
use
bacteria
also
virus
parasit
despit
success
conjug
vaccin
streptococcu
pneumonia
see
absenc
cross
protect
differ
serotyp
threat
serotyp
replac
strain
repres
vaccin
composit
make
unsuit
univers
use
identifi
appropri
vaccin
candid
whole
genom
sequenc
pneumonia
scan
potenti
orf
signific
homolog
surfac
protein
virul
factor
bacteria
identifi
protein
effect
express
e
coli
use
immun
mice
six
abl
confer
protect
pneumococc
challeng
mous
sepsi
model
flow
cytometri
confirm
surfac
local
new
protein
furthermor
six
protect
antigen
show
high
degre
cross
reactiv
major
capsular
antigen
express
vivo
immunogen
human
infect
provid
good
base
develop
improv
vaccin
pneumonia
streptococcu
agalactia
group
b
streptococcu
lead
caus
bacteri
sepsi
pneumonia
mening
neonat
us
europ
pneumonia
capsular
polysaccharid
major
protect
antigen
least
nine
differ
seroptyp
exist
littl
cross
protect
therefor
proteinbas
vaccin
requir
overcom
serotyp
differ
complet
genom
serotyp
v
strain
agalactia
determin
analyz
genom
predict
code
orf
predict
expos
surfac
bacteria
approxim
orf
success
express
e
coli
use
immun
mice
use
sera
elisa
flow
cytometr
analysi
intact
bacteria
demonstr
protein
fact
measur
express
surfac
bacterium
new
antigen
evalu
vitro
vivo
model
capac
protect
invas
infect
group
b
streptococcu
identifi
vaccin
candid
staphylococcu
aureu
approach
base
genom
peptid
librari
wellcharacter
human
sera
develop
aureu
peptid
display
surfac
e
coli
via
fusion
one
two
outer
membran
protein
lamb
fhua
probe
sera
select
high
antibodi
titer
opson
activ
exhaust
screen
two
differ
peptid
express
librari
applic
mac
technolog
magnet
cell
sort
enabl
profil
antigen
express
vivo
abl
elicit
immun
respons
human
identifi
total
antigen
protein
identifi
predict
secret
locat
surfac
bacterium
antibodybind
site
map
antigen
repres
promis
vaccin
candid
evalu
process
similar
one
use
develop
vaccin
menb
use
also
porphyromona
gingivali
pathogen
implic
etiolog
chronic
adult
periodont
genom
sequenc
gene
select
use
seri
bioinformat
tool
select
gene
clone
express
e
coli
screen
western
blot
use
sera
human
periodont
patient
anim
antisera
subset
recombin
protein
purifi
use
immun
mice
subsequ
challeng
live
bacteria
subcutan
abscess
model
two
recombin
protein
show
homolog
pseudomona
sp
oprf
protein
demonstr
signific
protect
anim
model
therefor
could
repres
potenti
vaccin
candid
chlamydia
pneumonia
oblig
intracellular
parasit
complex
biphas
lifecycl
extracellular
infecti
phase
character
sporelik
form
elementari
bodi
eb
intracellular
replic
stage
character
reticular
bodi
rb
pathogen
common
caus
communityacquir
acut
respiratori
infect
recent
also
associ
atherosclerot
cardiovascular
diseas
technic
difficulti
work
c
pneumonia
absenc
reliabl
tool
genet
manipul
much
known
cell
surfac
composit
eb
defin
surfac
protein
organ
c
pneumonia
systemat
genom
proteom
approach
use
approach
base
six
main
experiment
step
silico
analysi
c
pneumonia
genom
sequenc
identifi
gene
potenti
encod
surfac
protein
includ
outer
inner
membran
periplasm
protein
ii
clone
express
purif
select
candid
iii
use
purifi
antigen
gener
mous
immun
sera
iv
analysi
sera
specif
western
blot
total
eb
extract
v
assess
antigen
local
fac
analysi
whole
eb
vi
identif
facsposit
antigen
bidimension
electrophoresi
map
c
pneumonia
eb
protein
result
systemat
genomeproteom
approach
repres
first
success
attempt
defin
surfac
protein
organ
c
pneumonia
rais
possibl
find
suitabl
candid
purifi
vaccin
current
licens
anthrax
vaccin
develop
base
cellfre
filtrat
contain
mainli
protect
antigen
pa
pa
common
cellbind
domain
capabl
interact
two
differ
domain
lethal
edema
factor
elicit
cell
damag
vaccin
origin
licens
select
veterinari
personnel
textil
worker
abattoir
worker
wide
use
first
time
us
militari
desert
storm
campaign
howev
extend
use
rais
issu
controversi
regard
safeti
efficaci
unsatisfactori
dose
regimen
vaccin
requir
seri
inject
annual
booster
therefor
identif
novel
antigen
essenti
develop
secondgener
b
anthraci
vaccin
orf
product
similar
protein
involv
bacteri
pathogenesi
secret
surfac
expos
protein
focu
research
use
function
genom
analysi
candid
select
case
simpl
method
reli
vitro
translat
linear
fulllength
dna
select
orf
use
polypeptid
obtain
vitro
evalu
immunogen
analysi
reactiv
hyperimmun
antib
anthraci
antisera
combin
bioinformat
genom
analysi
effici
fast
screen
facilit
identif
unknown
antigen
protein
three
appear
similar
immunogen
pa
new
protein
could
repres
part
secondgener
anthrax
vaccin
old
plagu
vaccin
base
kill
whole
cell
prepar
although
appear
effect
endem
plagu
consid
protect
respiratori
plagu
form
concern
case
biolog
attack
moreov
vaccin
high
rate
reaction
system
local
especi
success
dose
suffer
short
durat
protect
requir
biannual
booster
liveattenu
vaccin
strain
also
exist
vaccin
seem
effect
retain
virul
countri
consid
suitabl
human
use
search
novel
attenu
vaccin
candid
use
pesti
signaturetag
mutagenesi
stm
strategi
use
librari
tag
mutant
virul
pesti
strain
gener
screen
mutant
two
consecut
cycl
result
select
mutant
strain
character
phenotyp
genotyp
select
mutant
led
identif
virulenceassoci
gene
code
factor
involv
global
bacteri
physiolog
eg
purh
purk
dnae
grea
hypothet
polypeptid
well
virul
regul
gene
lcrf
one
avirul
mutant
strain
found
disrupt
pcm
locu
presum
involv
bacteri
respons
environment
stress
mutant
superior
live
vaccin
strain
anim
model
mice
infect
subcutan
virul
pesti
strain
either
mutant
induc
antibodi
titer
protect
v
antigen
confer
efficaci
protect
immun
result
indic
mutant
mutat
pcm
locu
serv
platform
gener
novel
live
vaccin
promis
induc
efficaci
protect
immun
virul
pesti
strain
previous
suggest
mutant
sar
epidem
first
infecti
diseas
outbreak
fulli
benefit
revolutionari
technolog
postgenom
era
thank
unpreced
collabor
effort
scientist
mani
countri
coordin
includ
clinic
epidemiolog
laboratori
investig
within
day
issu
global
alert
caus
agent
new
diseas
discov
less
month
initi
identif
new
coronaviru
call
sarscov
infecti
agent
sar
two
independ
genom
sequenc
viru
obtain
within
three
month
genom
sequenc
independ
clinic
isol
made
avail
genbank
databas
rapid
avail
genom
sequenc
new
viru
import
public
health
perspect
give
prompt
answer
number
critic
question
clear
agent
natur
laboratoryfabr
coronaviru
diagnost
kit
set
possibl
drug
vaccin
target
identifi
today
vaccin
base
kill
viru
alreadi
test
preclin
even
clinic
trial
efficaci
need
shown
moreov
addit
tradit
approach
number
newer
strategi
use
includ
subunit
vaccin
contain
recombin
spike
protein
express
mammalian
cell
yeast
either
alon
combin
sarscov
antigen
altern
antigen
could
deliv
dna
immun
nonrepl
virus
viral
vector
base
adenoviru
canarypox
modifi
vaccinia
viru
ankara
mva
alphaviru
particular
develop
nonrepl
coronaviruslik
particl
mimic
structur
nativ
virion
could
prove
promis
search
success
vaccin
display
larg
repertoir
antigen
site
discontinu
epitop
crucial
rememb
none
approach
would
possibl
way
speed
without
knowledg
complet
genom
sequenc
viru
make
comparison
last
time
mankind
face
appear
new
pandem
earli
appear
hiv
time
year
ago
took
two
year
identifi
etiolog
agent
infect
safe
effect
vaccin
still
lack
edward
jenner
gave
birth
concept
vaccin
littl
could
know
year
mankind
would
still
battl
emerg
reemerg
infecti
diseas
howev
contemporari
societi
lucki
scienc
constantli
offer
effect
tool
combat
control
infecti
diseas
question
whether
mani
social
polit
cultur
econom
barrier
still
exist
vaccin
eventu
overcom
thu
recogn
real
valu
vaccin
